Johnson & Johnson's Q3 2018 earnings call indicates strong performance across segments, particularly in Pharmaceuticals.  Positive guidance updates suggest a continuation of this trend, with improved growth forecasts in both sales and earnings.  Management's confidence and focus on innovation and new product launches position the company for continued success.
[1]
